Brought to you by 
Series A for Pevion Biotech results in CHF35mm
15 Aug 2007
Executive Summary
Pevion Biotech (vaccines for infectious diseases and cancer) raised CHF35mm ($29.3mm) through its Series A financing led by first-time backer BZ Bank Aktiengesellschaft. Other new investors BB Biotech Ventures and CC Private Equity Partners were joined by returning shareholder Bachem Holding AG. The company will use the proceeds to move its Phase I hepatitis C and breast cancer vaccines into Phase II trials, and to advance its preclinical RSV and Candida vaccines into human studies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A for Pevion Biotech results in CHF35mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice